aibioRetension Pharmaceuticals prices IPO of 3,750,000 shares at $12.00
Tickers RTSN
The offering totals $45,000,000 before fees. The prospectus discloses a restatement of 2025 financial statements, a material weakness in internal control and going concern doubt.
Key facts
- Company
- Retension Pharmaceuticals, Inc. (NASDAQ: RTSN)
- News type
- Financings
- Primary source
- Retension Pharmaceuticals, Inc. 424B4 (2026-10-09)
Retension Pharmaceuticals, Inc. priced its initial public offering at $12.00 per share, according to a final prospectus filed on October 9, 2026. The company is selling 3,750,000 shares of common stock. The shares will list on the Nasdaq Capital Market under the symbol RTSN, and the underwriters expect delivery on or about October 13, 2026.
The offering totals $45,000,000 before fees. Underwriting discounts and commissions are $3,150,000, which leaves $41,850,000 in proceeds to the company before expenses. The company estimates net proceeds of about $38.9 million after offering expenses. The underwriters hold a 30-day option to buy up to 562,500 more shares, which would lift estimated net proceeds to about $45.1 million.
Underwriters and lock-ups
The cover names Leerink Partners, Guggenheim Securities, Oppenheimer & Co. and Titan Partners as underwriters. Retension has agreed to reimburse certain underwriter expenses. Lock-up agreements bar the company's directors, officers and holders of substantially all outstanding shares from selling for 180 days after the prospectus date, unless Leerink Partners LLC and Guggenheim Securities LLC consent. The underwriters may let insiders sell before that period ends.
Once the lock-ups expire, up to 4,582,047 additional shares become eligible for sale. Of those, 1,315,159 are held by directors, executive officers and other affiliates and remain subject to Rule 144 volume limits.
Ownership after the deal
The company's share count before the offering is 4,581,599 shares as of June 30, 2026, after automatic conversion of its Series A and Series B preferred stock. The prospectus table shows existing holders with 55.0 percent of shares after the offering and new investors with 45.0 percent. If the underwriters' option is exercised in full, existing holders would fall to 51.5 percent and new investors would hold 48.5 percent.
What the money is for
The company plans to spend about $18 million completing the Phase 2b trial of RTN-001 in uHTN and about $10 million preparing and running the planned Phase 3 trial. The rest goes to general corporate purposes and operating expenses. It may also use part of the proceeds for acquisitions or investments, but it says it has no agreements for any.
Retension says net proceeds plus existing cash will fund operations through at least the next 21 months. That is a longer runway than the company gave in its earlier filing, where cash of $13.5 million at June 30, 2026, down from $18.9 million at December 31, 2025, was not expected to fund operations for at least twelve months. The company's net loss was $7.5 million for the six months ended June 30, 2026, and its accumulated deficit reached $15.8 million.
Going concern and restatement
The prospectus still carries going concern language. Recurring losses and its financial condition raise substantial doubt about its ability to continue, and the auditor's report on the 2025 statements includes an explanatory paragraph to that effect. The company also restated its 2025 financial statements to correct an accounting error, identified a material weakness in internal control over financial reporting, and warns that further errors could be found.
The drug and its evidence
RTN-001 is a once-daily oral PDE-5 inhibitor for hypertension. The pilot evidence is small. In Trial 07-08, 40 hypertensive patients took the drug in a crossover trial that the prospectus says was not powered for statistical significance, and one timepoint for the 10 mg group had p = 0.0532. The company says those pilot results may not predict outcomes in the Phase 2b study or a Phase 3 trial, which are designed differently and enroll larger populations. Initial Phase 2b data are expected in the first half of 2027.
Retension also carries a cost from its licensing chain. Under the Redux agreement, it assumed royalty obligations that Redux owed to Kadmon, a low-teens percentage of net sales of RTN-001 and a low-teens percentage of sublicensing revenue. Kadmon is now a Sanofi subsidiary. The prospectus says Eric Keller and Paul Sweetnam, the company's chief executive and chief scientific officer, are each a manager of Redux.
The prospectus lists the 2025 restatement and the material weakness in internal control among the risks of buying the shares.